Table 1 Summary of equilibrium (Day 3–28) TFV and TFV-DP concentrations during implant use.

Low, TFV, plasma

nM

ng mL^-1

10

70^c

183.5 (12.4–253.1)

52.7 (4.2–72.7)

Low, TFV-DP, PBMC

nM

fmol/10⁶ cells

15

100

772.9 (387.8–4,306)

154.6 (77.6–861.1)

Low, TFV, dermal tissue

fmol mg^-1

ng mg^-1

15

100

82.6 × 10³ (57.0 × 10³–415.0 × 10³)

23.7 (16.4–119.2)

Low, TFV-DP, dermal tissue

fmol mg^-1

15

100

1.448 (518.6–2.429)

High, TFV, plasma

nM

ng mL^-1

15

100

1.070 (673.5–1.695)

307.4 (193.5–486.8)

High, TFV-DP, PBMC

nM

fmol/10⁶ cells

15

100

14,987 (8.784–21,531)

2.997 (1.757–4.306)

High, TFV, dermal tissue

fmol mg^-1

ng mg^-1

15

100

540.1 × 10³ (292.1 × 10³–1.156 × 10³)

155.1 (83.9–332.1)

High, TFV-DP, dermal tissue

fmol mg^-1

15

100

6.303 (2.351–8.846)